China Diabetes Market Report & Outlook For 2010-2015

September 2010 | 89 pages | ID: CFF9597AD64EN
IMARC Group

Abstracts

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined.

China’s diabetes market grew at CAGR of 26% in the last five years with sales touching US$ 642 Million in 2009. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis-a-vis its present level by 2015.

IMARC’s new report 'China Diabetes Market Report & Outlook for 2010-2015' gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

Report Highlights

• Driven by strong performance of both Insulin and Non-Insulin Anti-diabetics, The Chinese diabetes market is expected to exceed US$ 2.8 Billion by 2015.
• In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.
• Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.
• Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.
• China’s Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.
• The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.

Forecasts: The report provides forecasts on:

• Number of diabetes patients
• Diagnosis and treatment rates in China
• Diabetes market
• Non-Insulin Anti-diabetics market
• Alpha-Glycosidase Inhibitors
• Glinides
• Glitazones
• Sulphonylureas
• DPP-IV Inhibhitors
• Biguanides
• GLP-1 Agonists
• All other Non-Insulin Anti-diabetic classes
• Insulin market

Competitive Landscape: This section covers:

• 2005-2009 sales and market shares of top players in the diabetes market
• 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
• 2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes
• 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes
• 2005-2009 sales and market shares of top players in the Insulin market
• 2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market.

Key Questions Answered in this report

• What is the total size of the diabetes population in China and what are its characteristics?
• What are the diagnosis and drug treatment rates for diabetes in China?
• What are the key factors driving the growth of diabetes medication in China?
• What is the Size and Breakup of the total diabetes market in China?
• What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China?
• What is the Size and Breakup of the total Insulin market in China?
• Who are the key players in the Chinese diabetes market and how have they performed?
• What is the outlook of the Chinese diabetes market in the next five years?
• Which new products are expected to be launched in the next five years?
• Which therapy classes will show the highest growth in the next five years?
• What are the road blocks in the Chinese diabetes market?

Contents

1. EXECUTIVE SUMMARY

2. DIABETES DISEASE OVERVIEW

2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
  2.2.1 Diagnosis
  2.2.2 Treatment
2.3 DIABETES COMPLICATIONS

3. THE CHINESE DIABETES MARKET: WHY IS IT SO LUCRATIVE?

3.1 CHINA HAS THE ONE OF THE LARGEST DIABETES PATIENT POOLS IN THE WORLD.
3.2 CHINA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 INCREASING AFFORDABILITY OF HEALTHCARE
3.4 MORE THAN A BILLION DOLLAR WORTH OF MARKET REMAINS UNTAPPED
3.5 A BETTER IPR REGIME IS DRIVING THE LAUNCH NEW AND INNOVATIVE DRUGS

4. DRIVERS OF DIABETES IN CHINA

4.1 AGEING POPULATION
4.2 INCREASING OBESITY LEVELS
4.3 URBANIZATION

5. THE CHINESE DIABETES EPIDEMIOLOGY

5.1 TOTAL PREVALENCE
  5.1.1 Urban and Rural Prevalence
  5.1.2 Prevalence of Diabetes by Sex
  5.1.3 Prevalence of Diabetes by Age Group
5.2 DIAGNOSIS AND TREATMENT RATES IN CHINA

6. THE CHINESE DIABETES MARKET

6.1 MARKET TREND (2005-2009)
6.2 MARKET SEGMENTATION (2005-2009)
6.3 MARKET FORECASTS (2010-2015)

7. THE CHINESE NON-INSULIN ANTI-DIABETICS MARKET

7.1 MARKET TREND (2005-2009)
7.2 COMPETITIVE LANDSCAPE (2005-2009)
7.3 MARKET FORECASTS (2010-2015)
7.4 MARKET SEGMENTATION (2005-2015)
  7.4.1 Alpha-Glycosidase Inhibitors
    7.4.1.1 Market Trend (2005-2009)
    7.4.1.2 Competitive Landscape
      7.4.1.2.1 Share of Key Players
      7.4.1.2.2 Portfolio of Key Players
    7.4.1.3 Market Forecasts (2010-2015)
  7.4.2 Glinides
    7.4.2.1 Market Trend (2005-2009)
    7.4.2.2 Competitive Landscape
      7.4.2.2.1 Share of Key Players
      7.4.2.2.2 Portfolio of Key Players
    7.4.2.3 Market Forecasts (2010-2015)
  7.4.3 Glitazones
    7.4.3.1 Market Trend (2005-2009)
    7.4.3.2 Competitive Landscape
      7.4.3.2.1 Share of Key Players
      7.4.3.2.2 Portfolio of Key Players
    7.4.3.3 Market Forecasts (2010-2015)
  7.4.4 Sulphonylureas
    7.4.4.1 Market Trend (2005-2009)
    7.4.4.2 Competitive Landscape
      7.4.4.2.1 Share of Key Players
      7.4.4.2.2 Portfolio of Key Players
    7.4.4.3 Market Forecasts (2010-2015)
  7.4.5 Biguanides
    7.4.5.1 Market Trend (2005-2009)
    7.4.5.2 Competitive Landscape
      7.4.5.2.1 Share of Key Players
      7.4.5.2.2 Portfolio of Key Players
    7.4.5.3 Market Forecasts (2010-2015)
  7.4.6 Dpp-IV Inhibitors
    7.4.6.1 Competitive Landscape
      7.4.6.1.1 Share Forecast for Key Players
      7.4.6.1.2 Portfolio of Key Players
    7.4.6.2 Market Forecasts (2010-2015)
  7.4.7 Glp-1 Agonists
    7.4.7.1 Competitive Landscape
      7.4.7.1.1 Share Forecast for Key Players
      7.4.7.1.2 Portfolio of Key Players
    7.4.7.2 Market Forecasts (2010-2015)
  7.4.8 All other Classes
    7.4.8.1 Market Trend (2005-2009)
    7.4.8.2 Competitive Landscape
      7.4.8.2.1 Share of Key Players
      7.4.8.2.2 Portfolio of Key Players
    7.4.8.3 Market Forecasts (2010-2015)

8. THE CHINESE INSULIN MARKET

8.1 MARKET TREND (2005-2009)
8.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
8.3 MARKET SEGMENTATION BY MODE OF ACTION
8.4 COMPETITIVE LANDSCAPE
  8.4.1 Share of key Players
  8.4.2 Insulin Portfolio of Key Players
8.5 MARKET FORECASTS (2005-2010)

9. ROAD BLOCKS

9.1 MILLIONS DON’T EVEN KNOW IF THEY HAVE DIABETES
9.2 DESPITE THE LARGE POPULATION BASE, AVERAGE SPENDING ON DIABETES REMAINS FAIRLY LOW
9.3 REGULATORY & BUREAUCRATIC HURDLES
9.4 LARGE FINANCIAL DISPARITY

List Of Figures

LIST OF FIGURES

Figure 2:1: The impact of Diabetes in the Human Body
Figure 2:2: Diabetes Complications
Figure 3:1: China - Personal Disposable Income (in US$ per Head), 2005-2015
Figure 3:2: China - Breakup of Consumer Expenditure (%), 2007, 2010 & 2015
Figure 3:3: China: Tapped and Untapped Diabetes Market, (in Million US$), 2010
Figure 4:1: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65-99), (In Million), 2005, 2010, 2015, 2020, 2025
Figure 4:2 : China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65-99), (in %),
Figure 4:3 : China: Diabetes Prevalence Forecast by age groups, (in %),
Figure 4:4: China: Overweight & Obese Patient Forecast, (in Million), 2005, 2010, 2015, 2020 & 2025
Figure 4:5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 4:6: China: Prevalence of Diabetes by Region (%), 2002
Figure 4:7: China: Prevalence of overweight and Obesity by Region (%), 2002
Figure 5:1: China: Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 5:2: China: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 5:3: China (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 5:4: China (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 5:5: China: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030
Figure 5:6: China (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 5:7: China (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 5:8: China: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030
Figure 5:9: China: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 5:10: China: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 5:11 : China: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030
Figure 5:12: China: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015
Figure 6:1: China: Diabetes Market, (in Million US$), 2005-2009
Figure 6:2: China: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:3: China: Diabetes Market, (in Million US$), 2010-2015
Figure 6:4: China: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:5: China: Contribution of Non-insulin Anti-diabetics & Insulin towards Total Growth,
Figure 7:1: China: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:2: China: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:3: China: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:4: China: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Classes (in %),
Figure 7:5: China: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015
Figure 7:6: China: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:7: China: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %),
Figure 7:8: China: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$),
Figure 7:9: China: Glinide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:10: China: Glinide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:11: China: Glinide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:12: China: Glitazone Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:13: China: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:14: China: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:15: China: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:16: China: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %),
Figure 7:17: China: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:18: China: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:19: China: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:20: China: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:21: China: DPP-IV Inhibitors, Value Market Share Forecast of Key Players (in %),
Figure 7:22: China: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:23: China: Glp-1 Agonist Anti-diabetics Market, Value Market Shares of Key Players
Figure 7:24: China: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:25: China: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:26: China: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players
Figure 7:27: China: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015
Figure 8:1: China: Insulin Sales, (in Million US$), 2005-2009
Figure 8:2: China: Insulin Market, Value Market Shares of Key Molecules (in %),
Figure 8:3: China: Insulin Market, Value Market Shares by Mode of Action (in %), 2009
Figure 8:4: China: Insulin Market, Value Market Shares of Key Players (in %), 2005-2009
Figure 8:5: China: Insulin Sales Forecast, (in Million US$), 2010-2015
Figure: 9:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets, 2010

List Of Tables

LIST OF TABLES

Table 1 1: Diagnosis of Diabetes
Table 2 1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030
Table 2 2: Statistics of Top Emerging and Developed Diabetes Markets 2009
Table 2 3: Drugs Expected to be launched in the Chinese Diabetes Market, 2010-2015
Table 4 1: China: Total Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015
Table 6 1: China: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 2: China: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$),
Table 6 3: China: Non-Insulin Anti-diabetics Market, Value Shares of Key Classes (in %),
Table 6 4: China: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$),
Table 6 5: China: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %),
Table 6 23: China: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$),
Table 6 24: China: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 25: China: Hangzhou’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 26: China: Sc.lz.Baoguang’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 27: China: Takeda’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 28: China: Jiangsu’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 35: China: Glinide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 36: China: Novo Nordisk Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 37: China: JS.L.Y.G. Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 38: China: Novartis’s Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 39: China: Js.Yangzijiang Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 6: China: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 7: China: GlaxoSmithKline’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 8: China: Sichuan Taiji Ph’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 9: China: Beijing Taiyang’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 10: China: JS.L.Y.G.’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 11: China: Hangzhou’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 17: China: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 18: China: Servier Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 19: China: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 20: China: Shuanghe Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 21: China: Pfizer’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 22: China: Shanghai Fosun’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 12: China: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 13: China: Bristol-Myers Biguanide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 14: China: Bj.Liling Hengtai Biguanide Portfolio Sales (in 000’ US$),
Table 6 15: China: C.T-Tianqing Biguanide Portfolio Sales (in 000’ US$),
Table 6 16: China: Guizhou Biguanide Portfolio Sales (in 000’ US$),
Table 6 29: China DPP-IV Inhibitors, Sales Forecast of Key Players (in 000’ US$), 2010 & 2015
Table 6 30: China: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2010 & 2015
Table 6 33: China: BMS /AstraZeneca DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 34: China: Boehringer Ingelheim’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 32: China: Takeda’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 31: China: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 40: China: Glp-1 Agonist Anti-diabetics Market, Sales Forecast of Key Players (in 000’ US$), 2008 & 2009
Table 6 41: China: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 42: China: Novo Nordisk’s Glp-1 Agonist Portfolio Sales (in 000’ US$),
Table 6 43: China: Ipsen/Roches’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 44: China: Sanofi Aventis’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 45: China: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 46: China: Js.Nj.Hailing Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 47: China: Sh.Xiandai’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 48: China: YabaoTaiyuan All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 49: China: C.T-Tianqing All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 50: China: Shanghai Fosun All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 7 1: China: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009
Table 7 2: China: Insulin Value Shares by Molecule (in %), 2005-2009
Table 7 3: China: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009
Table 7 4: China: Insulin Value Shares by Mode of Action (in %), 2005-2009
Table 7 5: China: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 7 6: China: Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 7: China: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 8: China: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 9: China: Tonghua Dongbao’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 10: China: Bj Ganli Pharma’s Insulin Portfolio Sales (in 000’ US$), 2005-2009

COMPANIES MENTIONED

Hangzhou
Sc.lz.Baoguang
Takeda
Jiangsu
Servier
Sanofi-Aventis
Shuanghe
Pfizer
Shanghai Fosun
Novo Nordisk
JS.L.Y.G.
Novartis
Js.Yangzijiang
Glaxosmithkline
Sichuan Taiji Ph
Beijing Taiyang
Bristol-Myers
Bj.Liling Hengtai
C.T-Tianqing
Guizhou
Js.Nj.Hailing Ph
Sh.Xiandai
YabaoTaiyuan
Shanghai Fosun
Lilly

PRODUCTS MENTIONED

Glipizide+Metformin
Glibenclami
Metformin
Glimepiride+Metformin
Metformin+Voglibose
Glipizide+Metformin
Gliciazide+Metformin
Glimepiride+Metformin
Glibenclamide
Glimepiride+Pioglitazone+ Metaformin
Pioglitazone
Metformin+Pioglitazone
Glimepiride+Pioglitazone+Metaformin
Metformin Pioglitazone
Glimepiride+Pioglitazone
Melformin+ Rosiglitazone
Glimepiride
Gliclazide
Glipizlde
Glieiazide+Pioglitazone
Acarbose
Voglibose
Miglitol
Sitagliptin
Metformin+Sitagliptin
Vildagliptin
Metformin+Vildagliptin
Mecobalami
Gymnema
Repaglinide
Nateglinide
Metformin+Nateglinide
Exenatide
Exenatide
Exenatide LAR
Liraglutide
Lixisenatide
Taspoglutide
Albiglutide
LY-2189265
Alogliptin
Saxagliptin
Linagliptin
Ka Bo Ping
Acarbose
Basen
Ji Neng
Diamicron
Amaryl
Glurenorm
Glibenclamide
Glipizide Pfiz
Minidiab
Wan Su Ping
Novonorm
Fu lai Di
Starlix
Tang Rui
QiFu
Avandia
Avandamet
Tai luo
Actins
Rui Tong
Ka Si Ping
Glucophage
Metformin
Tao Bai
Ph Tang Lin
Tang Ke Ting
Thioctic Acid
Yi Fan Li
Byetta
Januvia
Janumet
Galvus
Eucreas
Nesina
Onglyza
Ondero
Bydureon
Victoza
Insulin
Oral-antidiabetics
Biguanide Antidiabetics
Glitazone Antidiabetics
Sulpphonylurea Antidiabetics
Alpha-Glucosidase Inhibhitor Antidiabetics
Dpp-IV Inhibhitor Antidiabetics
Other Drugs for Diabetes
Glinide Antidiabetics
Glp-1 Agonist Antidiabetics